3 completed, 1 terminated, 1 withdrawn. 2 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 2 | Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow bevasiranib: new trials by email Literature Review of bevasiranib trials Research Report on bevasiranib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON) Bevasiranib, ranibizumab - Age Related Macular Degeneration | Phase 3 | Withdrawn | OPKO Health, Inc. | 2009-11-01 | 2015-03-06 | |
| Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD bevasiranib, ranibizumab - Macular Degeneration | Phase 3 | Terminated | OPKO Health, Inc. | 338 | 2007-08-01 | 2014-10-06 |
| Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema bevasiranib - Diabetic Macular Edema | Phase 2 | Completed | OPKO Health, Inc. | 48 | 2006-01-01 | 2008-07-25 |
| Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration Bevasiranib - Macular Degeneration | Phase 2 | Completed | OPKO Health, Inc. | 120 | 2005-07-01 | 2008-08-05 |
| Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5 bevasiranib - Macular Degeneration | Phase 1 | Completed | OPKO Health, Inc. | 15 | 2004-08-01 | 2008-07-25 |
Macular Degeneration (4) · Edema (1) · Retinal Diseases (1) · Wet Macular Degeneration (1)
United States (4) · Canada (1)
Christine Du Castel, MD (1) · Denis O'Shaughnessy, PHD (1) · Denis O'Shaughnessy, Ph.D. (1) · Naveed Shams, MD (1)